The study identifies eight genes associated with resistance to various compounds targeting Mycobacterium tuberculosis, including eccB3, mmpL3, pks13, aspS, rv0678, rv1685c, ethA, and ndhA. Each gene was experimentally validated through recombineering and whole-genome sequencing.

The study identifies several mutations in Mycobacterium tuberculosis that confer resistance to various antibiotics, including isoniazid, rifampicin, streptomycin, fluoroquinolones, pyrazinamide, ethionamide, bedaquiline, clofazimine, and kanamycin. These mutations were found to evolve over five years of treatment in a patient with inadequate compliance.

The study identifies IS6110-mediated gene disruptions in clinical Mycobacterium tuberculosis strains that lead to resistance against bedaquiline, clofazimine, ethionamide, pyrazinamide, and para-aminosalicylic acid.

The study identified Rv0678 as a gene associated with bedaquiline resistance in MDR-TB isolates, with nonsynonymous nonsilent mutations in Rv0678 linked to reduced susceptibility to bedaquiline.

The study identified Rv0678 mutations as a significant factor in bedaquiline resistance among drug-resistant tuberculosis cases in Taiwan, with several novel mutations detected.

The study evaluates the performance of the GeneLEAD VIII and Deeplex Myc-TB assay for detecting drug resistance in Mycobacterium tuberculosis complex. It identifies several AMR genes and mutations associated with resistance to various antituberculous drugs.

The study evaluates the performance of the GeneLEAD VIII and Deeplex Myc-TB assay for detecting drug resistance in Mycobacterium tuberculosis complex. It identifies several AMR genes and mutations associated with resistance to various antituberculous drugs.

The study reports the first identification of extensively drug-resistant Mycobacterium tuberculosis clinical isolates with resistance to bedaquiline, linezolid, and clofazimine in Uganda, highlighting the importance of adherence to treatment and the need for improved surveillance and diagnostics.

Mutations in rv0678 and a novel gene glpK were identified as contributing to bedaquiline resistance in Mycobacterium tuberculosis.

The study identifies collateral drug resistance and sensitivity in drug-resistant M. tuberculosis strains, highlighting the potential to exploit these phenomena for therapeutic strategies.

The study identified 265 genomic variants implicated in bedaquiline resistance, primarily in the Rv0678 gene, which regulates the MmpS5-MmpL5 efflux pump. Variants in atpE were also found to contribute to bedaquiline resistance. A large-scale genomic rearrangement involving Rv0678 was discovered as a new resistance mechanism.

The study identified Rv0678 and pepQ mutations as the primary mechanisms of bedaquiline resistance in rifampicin-resistant Mycobacterium tuberculosis isolates from Zhejiang, China.

The study evaluated the effectiveness of NanoTNGS in detecting multidrug resistance in tuberculosis, identifying key mutations in genes such as rpoB, katG, embB, pncA, rpsL, gyrA, and rv0678 that confer resistance to various anti-tubercular drugs.

The study identifies several genes and mutations associated with drug resistance in Mycobacterium tuberculosis, including pncA, ethA, ndh, mshA, embR, rpoB, inhA, gyrA, and Rv0678, along with their respective mutations that confer resistance to pyrazinamide, ethionamide, isoniazid, rifampicin, ethambutol, fluoroquinolones, bedaquiline, and clofazimine.

The study identified mutations in the Rv0678 gene as a significant factor in bedaquiline resistance among Mycobacterium tuberculosis isolates, with various frameshift mutations contributing to reduced susceptibility.

The study introduces LLMTB, a large language model that predicts antibiotic resistance in Mycobacterium tuberculosis by analyzing genomic data. It identifies key resistance genes and intergenic regions associated with various antibiotics, demonstrating superior performance compared to existing methods.

Rv0677c and Rv0191 efflux pump genes were identified as the primary contributors to rifampin resistance in rpoB mutant Mycobacterium tuberculosis strains, with their overexpression significantly affecting MIC values and resistance levels.